GSE161072
Global transcriptomics of murine splenic B cells after treatment with BAFF 3mer and 60mer in presence of a control antibody or mBaffR-mFc
Mouse splenic total B cells (6 million cells/sample) were pre-treated with the control Ab (1000ng/ml, IgG1?, BioXCell, #BE0083) or mBaffR-mFc (1000ng/ml, a fusion protein consists of murine BR3 ecto-domain fused to murine IgG1 Fc fragment obtained from Biogen, US) for 30 min, and then treated with 100 ng/ml of recombinant human BAFF 3mer (AdipoGen, #AG-40B-0016), 60mer (AdipoGen, #AG-40B-0112) or left untreated for the next 4 hours. Each treatment was in triplicates. Total RNA was extracted from the samples using QIAGEN RNeasy Mini Kit and were sent to Novogene Corporation (Wilmingtom, DE, USA) to determine the gene expression levels. Overall design: Examination of the effect of BAFF 3mer and 60mer in B cell transcriptomics in presence or absence of a reagent that blocks BR3 binding sire on BAFF